Baricitinib for atopic dermatitis patients who responded inadequately to dupilumab treatment: First daily practice results

Abstract

Background: Baricitinib is the first JAK inhibitor registered for the treatment of moderate-to-severe atopic dermatitis (AD). Efficacy and safety were shown in clinical trials, but daily practice data is sparse. Objectives: To evaluate the effectiveness and safety of baricitinib treatment in daily practice in AD patients who have inadequately responded to dupilumab. Methods: In this prospective observational cohort study, AD patients who failed dupilumab treatment and started baricitinib treatment in context of standard care at the Erasmus MC (the Netherlands) were included. We analysed physician-reported scores and patient-reported outcome measure scores (PROMs). Results: Twenty-five patients were included. Baricitinib treatment resulted in significant improvement of Eczema Area and Severity Index (EASI) scores and PROMs. Seven patients showed a good and sustained response (EASI50), eight patients showed no response (